Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 6-month target price of 161.52 CNY, representing a dynamic price-to-earnings ratio of 60 times for 2025 [4][9]. Core Viewpoints - The company is positioned as a leading domestic player in medical imaging, with a strong focus on innovation and technology, comparable to top international manufacturers [1][14]. - The medical imaging industry is experiencing sustained growth, with China's market expected to grow at a compound annual growth rate (CAGR) of around 10% until 2030, significantly outpacing global growth [2][3]. - The company is witnessing a notable increase in both domestic and international market shares, with a CAGR of 93% in overseas revenue from 2018 to 2024 [3][9]. Summary by Sections Company Overview - The company has established itself as a leader in the domestic medical imaging sector since its inception in 2011, with a focus on high-quality product offerings and a robust R&D capability [14][16]. - The product line includes high-end medical imaging diagnostic products and radiation therapy products, aligning closely with offerings from international competitors like GE Healthcare and Siemens [1][21]. Core Growth Logic 1: Industry Growth - The global medical imaging equipment market surpassed 43 billion USD in 2020 and is projected to reach 63 billion USD by 2030, with a CAGR of nearly 4% [2]. - China's medical imaging market is expected to capture nearly 20% of the global market share by 2030, driven by high-end product demand and expanding market needs [2]. Core Growth Logic 2: Market Share Increase - The company has been rapidly increasing its market share domestically, with significant room for growth as current market shares for various product categories hover around 20% [3]. - The company's international strategy has led to a substantial increase in overseas revenue, which now accounts for approximately 20% of total revenue [3]. Marginal Catalysts - The medical equipment industry is experiencing a recovery in procurement and bidding processes, with a notable increase in tender amounts observed in early 2025 [4][8]. - The anticipated recovery in the industry is attributed to several factors, including a reasonable base for 2024, the revival of routine procurement, and accelerated construction of medical community systems [8]. Financial Forecast and Valuation - The company is expected to achieve revenue growth rates of 24.1%, 21.5%, and 20.2% for the years 2025 to 2027, with net profit growth rates of 75.8%, 19.8%, and 23.6% respectively [9][10].

Core Viewpoint - The company has released its 2024 ESG report, highlighting its initiatives and achievements in environmental, social, and governance areas, with a strong focus on green and low-carbon development [1] Group 1: Environmental Initiatives - The company has established a cross-departmental carbon management team and set clear greenhouse gas reduction targets, aiming to reduce Scope 1 and Scope 2 carbon emission intensity by 50% by 2035, using 2023 as the baseline [1] - In 2024, the company's greenhouse gas emissions amounted to 54,443.92 tons CO2e (Scope 1 and Scope 2, based on market), representing a 28% reduction (21,000 tons CO2e) compared to the 2023 baseline [1] - The greenhouse gas emission intensity decreased to 5.29 tons CO2e per million revenue, a year-on-year decline of 21%, with 41% of the mid-term goal of a 50% reduction by 2035 already achieved [1] Group 2: Technological Advancements - The company has launched the world's first silicon carbide MRI, which improves intelligent diagnostic efficiency by 30% and reduces equipment energy consumption by 57% [2] - The new generation PET/CT product utilizes more environmentally friendly materials and technologies to replace traditional lead shielding structures, effectively reducing environmental pollution [2] - The breast DR limiter innovatively uses steel instead of lead for X-ray limiting and shielding, achieving environmentally friendly and harmless solutions [2] - In the transportation segment, the company employs cold chain transportation technology for MRI equipment, significantly reducing liquid helium consumption, saving nearly 700,000 liters in 2024 [2]